

# ROSETTA GENOMICS™

Revealing Genomic Answers

## **Rosetta Genomics Expands Patent Portfolio in Europe and Japan**

*Granted European Patent Allowance and Japanese Patent for microRNA-based Lung Cancer Classifier*

*Fortifies Leading microRNA Diagnostic Patent Position and Creates New Opportunities for International Distribution and Intellectual Property Monetization*

**PHILADELPHIA and REHOVOT, Israel (May 1, 2017)** – Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces that the European Patent Office (EPO) has allowed its patent application (EP2691545) and the corresponding patent application has been granted by the Japan Patent Office (JPO) for Japanese Patent Application No. 2016-213582, both covering a method for classifying lung cancer as squamous cell carcinoma, non-squamous non-small cell lung cancer (NSCLC), carcinoid lung cancer or small cell lung carcinoma using a combination of eight microRNAs and a Rosetta proprietary algorithm.

“We are delighted to expand the intellectual property around our lung cancer classifier to Europe and Japan, as this is a cutting-edge molecular diagnostic test that uses microRNAs to accurately differentiate the four main histological subtypes of lung cancer, helping clinicians make informed patient care decisions and these are major international markets for this and other assays of ours,” stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. “Misclassification of lung cancer is a significant problem. Histological differences between tumor types can be subtle and variability between observers in classification occurs relatively frequently. This diagnostic dilemma has become critically important as new lung cancer treatments that are tumor specific require accurate sub-classification to optimize treatment plans.”

“These new patents are important to protecting our global leadership position in microRNA technology and the resulting diagnostic tests,” he added. “Moreover, it underscores the innovation of our assays and strengthens our position to establish international distribution agreements as the commercial interest in our microRNA-based assays continues to grow internationally.”

### **About Rosetta Genomics**

Rosetta is pioneering the field of molecular diagnostics by offering rapid and accurate diagnostic information that enables physicians to make more timely and informed treatment decisions to improve patient care. Rosetta has developed a portfolio of

unique diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists and other specialists to help them deliver better care to their patients. RosettaGX Reveal™, a Thyroid microRNA Classifier for the diagnosis of cancer in thyroid nodules, as well as the full RosettaGX™ portfolio of cancer testing services are commercially available through the Company's Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs.

**Forward-Looking Statement Disclaimer**

Various statements in this release, including, but not limited to statements relating to monetizing its intellectual property, expanding its distribution network, and growing commercial interest internationally constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's most recently filed Annual Report on Form 20-F, as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

**Rosetta Genomics Contact:**

Ken Berlin, President & CEO  
(267) 298-1159  
[investors@rosettagx.com](mailto:investors@rosettagx.com)

**Rosetta Genomics Investor Contact:**

LHA  
Anne Marie Fields  
(212) 838-3777  
[afields@lhai.com](mailto:afields@lhai.com)

# # #